• Biohaven Reports Positive Results from BHV-0223 Trial americanpharmaceuticalreview
    August 17, 2018
    Biohaven announced positive results from a double-blind, placebo-controlled, proof of concept clinical trial evaluating the effect of BHV-0223 in patients diagnosed with social anxiety disorder and public speaking anxiety while performing an anxiety-provo
  • Biohaven Doses First Subject in Bioequivalence Study with BHV-0223 americanpharmaceuticacreview
    November 07, 2017
    Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS).
PharmaSources Customer Service